Last reviewed · How we verify

ropivacaine mixed with dexmedetomidine

The First Hospital of Qinhuangdao · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while dexmedetomidine activates alpha-2 adrenergic receptors to enhance analgesia and sedation.

Ropivacaine blocks sodium channels to provide local anesthesia, while dexmedetomidine activates alpha-2 adrenergic receptors to enhance analgesia and sedation. Used for Regional anesthesia and analgesia for surgical procedures, Local infiltration anesthesia with enhanced analgesia.

At a glance

Generic nameropivacaine mixed with dexmedetomidine
SponsorThe First Hospital of Qinhuangdao
Drug classLocal anesthetic combination with alpha-2 adrenergic agonist
TargetVoltage-gated sodium channels (ropivacaine); alpha-2 adrenergic receptors (dexmedetomidine)
ModalitySmall molecule
Therapeutic areaAnesthesia and Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing action potential propagation and sensory/motor blockade. Dexmedetomidine is a selective alpha-2 adrenergic agonist that enhances the analgesic effect and provides sedation and anxiolysis when combined with local anesthetics, improving the quality and duration of regional anesthesia.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: